Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Charles River Laboratories | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Charles River Laboratories

1Q revenue climbs 20%

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Charles River Laboratories

1Q Revenues: $354.9 million (+20%)

1Q Earnings: $37.5 million (+19%)

Comments: Research Models and Services segment sales were $124.0 million in the quarter, up 3% driven by higher sales of both research models and research model services in North America, Europe, and Asia. Discovery and Safety Assessment segment revenues were $158.0 million, up 13% driven by growth in the Safety Assessment business. The Discovery Services business also grew, due primarily to the acquisition of Oncotest which contributed 2%. Manufacturing Support revenue was $72.9 million, up 21%, with the acquisitions of Celsis and Sunrise Farms contributing 15% to growth in the quarter. Revenue growth for the Biologics Testing Solutions business also contributed to theincrease.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters